Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
do-2
- Development stage
- Phase 1
- Lead developer
- DeuterOncology
- Modality
- Small Molecules
01
Overview
DO-2 is a small molecule drug under development by DeuterOncology. It acts as a dual inhibitor of the MET and RAS pathways and is investigated as a targeted therapy for lung cancer and other advanced malignant solid neoplasms. The compound specifically inhibits c-Met (hepatocyte growth factor receptor), which plays a role in tumor growth, survival, and metastasis. By targeting both MET and RAS signaling pathways, DO-2 aims to overcome resistance mechanisms seen with single-pathway inhibitors. As of June 2023, it is in Phase 1 clinical trials for non-small cell lung cancer (NSCLC) and other advanced solid tumors[6].
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on do-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on do-2.